Formulation and delivery of anti-HIV rectal microbicides: Advances and challenges

Journal of Controlled Release

Volumn 194, Issue , 2014, Pages 278-294

  Nunes, Rute ^a,b   Sarmento, Bruno ^a,b   Das Neves, José ^a,b  

^a INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^b INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

Author keywords

Drug formulation; HIV prevention; Rectal drug delivery; Safety; Topical PrEP

Indexed keywords

ANTI-HIV; DRUG FORMULATIONS; HIV PREVENTION; MICROBICIDES; TOPICAL PREP;

ACCIDENT PREVENTION;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BUFFER; EXCIPIENT; LUBRICATING AGENT; MICROBICIDE; ANTIRETROVIRUS AGENT;

DISEASE TRANSMISSION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; OSMOLALITY; PH; RECTUM; REVIEW; SHELF LIFE; ANIMAL; DRUG EFFECTS; FEMALE; HIV INFECTIONS; MALE; MEDICINAL CHEMISTRY; PHYSIOLOGY; RECTAL DRUG ADMINISTRATION; TRANSMISSION;

ADMINISTRATION, RECTAL; ANIMALS; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; FEMALE; HIV INFECTIONS; HUMANS; MALE; RECTUM;

EID: 84907681124     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.09.013     Document Type: Review

References (199)

1. UNAIDS Global Report: UNAIDS Report on the Global AIDS Epidemic. Geneva, Switzerland 2013
2. P.S. Sullivan, A. Carballo-Diéguez, T. Coates, S.M. Goodreau, I. McGowan, E.J. Sanders, A. Smith, P. Goswami, and J. Sanchez Successes and challenges of HIV prevention in men who have sex with men Lancet 380 2012 388 399
3. R.M. Grant, J.R. Lama, P.L. Anderson, V. McMahan, A.Y. Liu, L. Vargas, P. Goicochea, M. Casapía, J.V. Guanira-Carranza, M.E. Ramirez-Cardich, O. Montoya-Herrera, T. Fernández, V.G. Veloso, S.P. Buchbinder, S. Chariyalertsak, M. Schechter, L.G. Bekker, K.H. Mayer, E.G. Kallás, K.R. Amico, K. Mulligan, L.R. Bushman, R.J. Hance, C. Ganoza, P. Defechereux, B. Postle, F. Wang, J.J. McConnell, J.H. Zheng, J. Lee, J.F. Rooney, H.S. Jaffe, A.I. Martinez, D.N. Burns, and D.V. Glidden Preexposure chemoprophylaxis for HIV prevention in men who have sex with men N. Engl. J. Med. 363 2010 2587 2599
4. J.M. Baeten, D. Donnell, P. Ndase, N.R. Mugo, J.D. Campbell, J. Wangisi, J.W. Tappero, E.A. Bukusi, C.R. Cohen, E. Katabira, A. Ronald, E. Tumwesigye, E. Were, K.H. Fife, J. Kiarie, C. Farquhar, G. John-Stewart, A. Kakia, J. Odoyo, A. Mucunguzi, E. Nakku-Joloba, R. Twesigye, K. Ngure, C. Apaka, H. Tamooh, F. Gabona, A. Mujugira, D. Panteleeff, K.K. Thomas, L. Kidoguchi, M. Krows, J. Revall, S. Morrison, H. Haugen, M. Emmanuel-Ogier, L. Ondrejcek, R.W. Coombs, L. Frenkel, C. Hendrix, N.N. Bumpus, D. Bangsberg, J.E. Haberer, W.S. Stevens, J.R. Lingappa, and C. Celum Antiretroviral prophylaxis for HIV prevention in heterosexual men and women N. Engl. J. Med. 367 2012 399 410
5. M.C. Thigpen, P.M. Kebaabetswe, L.A. Paxton, D.K. Smith, C.E. Rose, T.M. Segolodi, F.L. Henderson, S.R. Pathak, F.A. Soud, K.L. Chillag, R. Mutanhaurwa, L.I. Chirwa, M. Kasonde, D. Abebe, E. Buliva, R.J. Gvetadze, S. Johnson, T. Sukalac, V.T. Thomas, C. Hart, J.A. Johnson, C.K. Malotte, C.W. Hendrix, and J.T. Brooks Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana N. Engl. J. Med. 367 2012 423 434
6. M.M. Solomon, J.R. Lama, D.V. Glidden, K. Mulligan, V. McMahan, A.Y. Liu, J.V. Guanira, V.G. Veloso, K.H. Mayer, S. Chariyalertsak, M. Schechter, L.G. Bekker, E.G. Kallás, D.N. Burns, and R.M. Grant Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis AIDS 28 2014 851 859
7. S.S. Karim, A.D. Kashuba, L. Werner, and Q.A. Karim Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women Lancet 378 2011 279 281
8. N.A. Louissaint, Y.J. Cao, P.L. Skipper, R.G. Liberman, S.R. Tannenbaum, S. Nimmagadda, J.R. Anderson, S. Everts, R. Bakshi, E.J. Fuchs, and C.W. Hendrix Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue AIDS Res. Hum. Retrovir. 29 2013 1443 1450
9. K.K. Ariën, V. Jespers, and G. Vanham HIV sexual transmission and microbicides Rev. Med. Virol. 21 2011 110 133
10. Z.A. Stein HIV prevention: the need for methods women can use Am. J. Public Health 80 1990 460 462
11. C. Beyrer, S.D. Baral, F. van Griensven, S.M. Goodreau, S. Chariyalertsak, A.L. Wirtz, and R. Brookmeyer Global epidemiology of HIV infection in men who have sex with men Lancet 380 2012 367 377
12. K. McBride, and D. Fortenberry Heterosexual anal sexuality and anal sex behaviors: a review J. Sex Res. 47 2010 123 136
13. R.F. Baggaley, R.G. White, and M.C. Boily HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention Int. J. Epidemiol. 39 2010 1048 1063
14. J.G. Rosenberger, M. Reece, V. Schick, D. Herbenick, D.S. Novak, B. Van Der Pol, and J.D. Fortenberry Sexual behaviors and situational characteristics of most recent male-partnered sexual event among gay and bisexually identified men in the United States J. Sex Med. 8 2011 3040 3050
15. C.S. Dezzutti, L.C. Rohan, L. Wang, K. Uranker, C. Shetler, M. Cost, J.D. Lynam, and D. Friend Reformulated tenofovir gel for use as a dual compartment microbicide J. Antimicrob. Chemother. 67 2012 2139 2142
16. A. Ham, W. Lustig, S. Nugent, J. Peters, D. Katz, C. Shelter, C. Dezzutti, A. Boczar, K. Buckheit, and R. Buckheit Formulation development of the DuoGel: a dual chamber vaginal/rectal anti-HIV microbicide gel 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, San Antonio, TX, USA 2013
17. I. McGowan The development of rectal microbicides for HIV prevention Expert Opin. Drug Deliv. 11 2014 69 82
18. E. van Hoogdalem, A.G. de Boer, and D.D. Breimer Pharmacokinetics of rectal drug administration, part I Clin. Pharmacokinet. 21 1991 11 26
19. A.G. de Boer, F. Moolenaar, L.G. de Leede, and D.D. Breimer Rectal drug administration: clinical pharmacokinetic considerations Clin. Pharmacokinet. 7 1982 285 311
20. J.M.N. Jorge, and A. Habr-Gama Anatomy and embryology D.E. Beck, P. Roberts, T.J. Saclarides, A.J. Senagore, M.J. Stamos, S.D. Wexner, The ASCRS Textbook of Colon and Rectal Surgery 2011 Springer New York, NY, USA 1 22
21. S.-X. Zhang An Atlas of Histology 1999 Springer New York, NY, USA
22. C.L. Bevins, and N.H. Salzman Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis Nat. Rev. Microbiol. 9 2011 356 368
23. L.P. Gartner, and J.L. Hiatt Color Atlas and Text of Histology 6th ed. 2014 Lippincott Williams & Wilkins Baltimore, MD, USA
24. N. Dujovny, R.M. Quiros, and T.J. Saclarides Anorectal anatomy and embryology Surg. Oncol. Clin. N. Am. 13 2004 277 293
25. M. Schuenke, E. Schulte, and U. Schumacher Neck and Internal Organs 1st ed. 2010 Thieme Stuttgart, Germany
26. R.A. Cone Barrier properties of mucus Adv. Drug Deliv. Rev. 61 2009 75 85
27. R.A. Cone Mucus J. Mestecky, M.E. Lamm, W. Strober, J. Bienenstock, J.R. McGhee, L. Mayer, Mucosal Immunology 2005 Academic Press San Diego, CA, USA 49 72
28. S.K. Linden, P. Sutton, N.G. Karlsson, V. Korolik, and M.A. McGuckin Mucins in the mucosal barrier to infection Mucosal Immunol. 1 2008 183 197
29. P. Borrow, R.J. Shattock, and A. Vyakarnam Innate immunity against HIV: a priority target for HIV prevention research Retrovirology 7 2010 84
30. V. Liévin-Le Moal, and A.L. Servin The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota Clin. Microbiol. Rev. 19 2006 315 337
31. R.D. Pullan, G.A. Thomas, M. Rhodes, R.G. Newcombe, G.T. Williams, A. Allen, and J. Rhodes Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis Gut 35 1994 353 359
32. R.P. MacDermott, R.M. Donaldson Jr., and J.S. Trier Glycoprotein synthesis and secretion by mucosal biopsies of rabbit colon and human rectum J. Clin. Invest. 54 1974 545 554
33. D.F. Evans, G. Pye, R. Bramley, A.G. Clark, T.J. Dyson, and J.D. Hardcastle Measurement of gastrointestinal pH profiles in normal ambulant human subjects Gut 29 1988 1035 1041
34. J.H. Rytting, and J.A. Fix Drug delivery: rectal route J. Swarbrick, Encyclopedia of Pharmaceutical Technology 2006 Informa Healthcare London, UK 1298 1310
35. A.S. Neish Microbes in gastrointestinal health and disease Gastroenterology 136 2009 65 80
36. J. Wilks, and T. Golovkina Influence of microbiota on viral infections PLoS Pathog. 8 2012 e1002681
37. O. Equils, K.K. Salehi, R. Cornataeanu, D. Lu, S. Singh, K. Whittaker, and G.C. Baldwin Repeated lipopolysaccharide (LPS) exposure inhibits HIV replication in primary human macrophages Microbes Infect. 8 2006 2469 2476
38. N. Ahmed, T. Hayashi, A. Hasegawa, H. Furukawa, N. Okamura, T. Chida, T. Masuda, and M. Kannagi Suppression of human immunodeficiency virus type 1 replication in macrophages by commensal bacteria preferentially stimulating Toll-like receptor 4 J. Gen. Virol. 91 2010 2804 2813
39. A.G. De Boer, L.G. De Leede, and D.D. Breimer Drug absorption by sublingual and rectal routes Br. J. Anaesth. 56 1984 69 82
40. M. Yun, H. Choi, J. Jung, and C. Kim Development of a thermo-reversible insulin liquid suppository with bioavailability enhancement Int. J. Pharm. 189 1999 137 145
41. D.R. Parker, G.D. Braatvedt, A. Bargiota, P.G. Newrick, S. Brown, G. Gamble, and R.J. Corrall Glucagon is absorbed from the rectum but does not hasten recovery from hypoglycaemia in patients with type 1 diabetes Br. J. Clin. Pharmacol. 66 2008 43 49
42. M. Yu, and M. Vajdy Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes Expert. Opin. Biol. Ther. 10 2010 1181 1195
43. N. Yagi, Y. Taniuchi, K. Hamada, J. Sudo, and H. Sekikawa Pharmacokinetics of ketotifen fumarate after intravenous, intranasal, oral and rectal administration in rabbits Biol. Pharm. Bull. 25 2002 1614 1618
44. M. Sakai, N. Hobara, N. Hokama, H. Kameya, S. Ohshiro, M. Sakanashi, and H. Saitoh Increased bioavailability of tacrolimus after rectal administration in rats Biol. Pharm. Bull. 27 2004 1480 1482
45. A. Desai Rectal, vaginal and urethral delivery A. Desai, M. Lee, Gibaldi's Drug Delivery Systems in Pharmaceutical Care 2007 American Society of Health-System Pharmacists Bethesda, MD, USA 95 102
46. Y. Watanabe Permeation pathways in rectal absorption E. Touitou, B.W. Barry, Enhancement in Drug Delivery 2010 CRC Press Boca Raton, FL, USA 135 144
47. M. Hayashi, M. Tomita, and S. Awazu Transcellular and paracellular contribution to transport processes in the colorectal route Adv. Drug Deliv. Rev. 28 1997 191 204
48. A. Yamamoto, and S. Muranishi Rectal drug delivery systems Improvement of rectal peptide absorption by absorption enhancers, protease inhibitors and chemical modification Adv. Drug Deliv. Rev. 28 1997 275 299
49. U. Klotz, and M. Schwab Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease Adv. Drug Deliv. Rev. 57 2005 267 279
50. C. Lautenschläger, C. Schmidt, D. Fischer, and A. Stallmach Drug delivery strategies in the therapy of inflammatory bowel disease Adv. Drug Deliv. Rev. 71 2014 58 76
51. A.T. Haase Early events in sexual transmission of HIV and SIV and opportunities for interventions Annu. Rev. Med. 62 2011 127 139
52. D.M. Butler, W. Delport, S.L.K. Kosakovsky Pond, M.K. Lakdawala, P.M. Cheng, S.J. Little, D.D. Richman, and D.M. Smith The origins of sexually transmitted HIV among men who have sex with men Sci. Transl. Med. 2 2010 18re1
53. D. Kolodkin-Gal, S.L. Hulot, B. Korioth-Schmitz, R.B. Gombos, Y. Zheng, J. Owuor, M.A. Lifton, C. Ayeni, R.M. Najarian, W.W. Yeh, M. Asmal, G. Zamir, and N.L. Letvin Efficiency of cell-free and cell-associated virus in mucosal transmission of human immunodeficiency virus type 1 and simian immunodeficiency virus J. Virol. 87 2013 13589 13597
54. S. Bernard-Stoecklin, C. Gommet, A.B. Corneau, S. Guenounou, C. Torres, N. Dejucq-Rainsford, A. Cosma, N. Dereuddre-Bosquet, and R. Le Grand Semen CD4 + T cells and macrophages are productively infected at all stages of SIV infection in macaques PLoS Pathog. 9 2013 e1003810
55. L.J. Abu-Raddad, A.S. Magaret, C. Celum, A. Wald, I.M. Longini, S.G. Self, and L. Corey Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa PLoS One 3 2008 e2230
56. J.S. Smith, S. Moses, M.G. Hudgens, C.B. Parker, K. Agot, I. Maclean, J.O. Ndinya-Achola, P.J. Snijders, C.J. Meijer, and R.C. Bailey Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection J. Infect. Dis. 201 2010 1677 1685
57. A. Nazli, O. Chan, W.N. Dobson-Belaire, M. Ouellet, M.J. Tremblay, S.D. Gray-Owen, A.L. Arsenault, and C. Kaushic Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation PLoS Pathog. 6 2010 e1000852
58. G. Meng, X. Wei, X. Wu, M.T. Sellers, J.M. Decker, Z. Moldoveanu, J.M. Orenstein, M.F. Graham, J.C. Kappes, J. Mestecky, G.M. Shaw, and P.D. Smith Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5 + cells Nat. Med. 8 2002 150 156
59. G. Fotopoulos, A. Harari, P. Michetti, D. Trono, G. Pantaleo, and J.P. Kraehenbuhl Transepithelial transport of HIV-1 by M cells is receptor-mediated Proc. Natl. Acad. Sci. U. S. A. 99 2002 9410 9414
60. K.B. Gurney, J. Elliott, H. Nassanian, C. Song, E. Soilleux, I. McGowan, P.A. Anton, and B. Lee Binding and transfer of human immunodeficiency virus by DC-SIGN + cells in human rectal mucosa J. Virol. 79 2005 5762 5773
61. J.C. Grivel, R.J. Shattock, and L.B. Margolis Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J. Transl. Med. 9 Suppl. 1 2011 S6
62. A.T. Haase Perils at mucosal front lines for HIV and SIV and their hosts Nat. Rev. Immunol. 5 2005 783 792
63. R.J. Shattock, and J.P. Moore Inhibiting sexual transmission of HIV-1 infection Nat. Rev. Microbiol. 1 2003 25 34
64. M. Aldunate, D. Tyssen, A. Johnson, T. Zakir, S. Sonza, T. Moench, R. Cone, and G. Tachedjian Vaginal concentrations of lactic acid potently inactivate HIV J. Antimicrob. Chemother. 2013 2015 2025
65. R.S. Veazey, and A.A. Lackner Getting to the guts of HIV pathogenesis J. Exp. Med. 200 2004 697 700
66. C. Lapenta, M. Boirivant, M. Marini, S.M. Santini, M. Logozzi, M. Viora, F. Belardelli, and S. Fais Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection Eur. J. Immunol. 29 1999 1202 1208
67. C.W. Hendrix, E.J. Fuchs, K.J. Macura, L.A. Lee, T.L. Parsons, R.P. Bakshi, W.A. Khan, A. Guidos, J.P. Leal, and R. Wahl Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates Clin. Pharmacol. Ther. 83 2008 97 105
68. Y.J. Cao, B.S. Caffo, E.J. Fuchs, L.A. Lee, Y. Du, L. Li, R.P. Bakshi, K. Macura, W.A. Khan, R.L. Wahl, L.A. Grohskopf, and C.W. Hendrix Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and magnetic resonance imaging Br. J. Clin. Pharmacol. 74 2012 1013 1022
69. N.A. Louissaint, S. Nimmagadda, E.J. Fuchs, R.P. Bakshi, Y. Cao, L.A. Lee, J. Goldsmith, B.S. Caffo, Y. Du, K.E. King, F.A. Menendez, M.S. Torbenson, and C.W. Hendrix Distribution of cell-free and cell-associated HIV surrogates in the colon following simulated receptive anal intercourse in men who have sex with men J. Acquir. Immune Defic. Syndr. 59 2012 10 17
70. M.J. McElrath, K. Smythe, J. Randolph-Habecker, K.R. Melton, T.A. Goodpaster, S.M. Hughes, M. Mack, A. Sato, G. Diaz, G. Steinbach, R.M. Novak, M. Curlin, J.D. Lord, J. Maenza, A. Duerr, N. Frahm, and F. Hladik Comprehensive assessment of HIV target cells in the distal human gut suggests increasing HIV susceptibility toward the anus J. Acquir. Immune Defic. Syndr. 63 2013 263 271
71. G.C. Preza, K. Tanner, J. Elliott, O.O. Yang, P.A. Anton, and M.T. Ochoa Antigen presenting cell candidates for HIV-1 transmission in human distal colonic mucosa defined by CD207 dendritic cells and CD209 macrophages AIDS Res. Hum. Retrovir. 30 2013 241 249
72. I.L. Cameron, J.E. Kent, R. Philo, C.J. Barnes, and W.E. Hardman Numerical distribution of lymphoid nodules in the human sigmoid colon, rectosigmoidal junction, rectum, and anal canal Clin. Anat. 19 2006 164 170
73. C. Beyrer, and Q. Abdool Karim The changing epidemiology of HIV in 2013 Curr. Opin. HIV AIDS 8 2013 306 310
74. D.M. Phillips, and V.R. Zacharopoulos Nonoxynol-9 enhances rectal infection by herpes simplex virus in mice Contraception 57 1998 341 348
75. D.L. Patton, Y.T. Cosgrove Sweeney, L.K. Rabe, and S.L. Hillier Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model Sex. Transm. Dis. 29 2002 581 587
76. J. Balzarini, and L. Van Damme Microbicide drug candidates to prevent HIV infection Lancet 369 2007 787 797
77. S.R. Tabet, C. Surawicz, S. Horton, M. Paradise, A.S. Coletti, M. Gross, T.R. Fleming, S. Buchbinder, R.C. Haggitt, H. Levine, C.W. Kelly, and C.L. Celum Safety and toxicity of nonoxynol-9 gel as a rectal microbicide Sex. Transm. Dis. 26 1999 564 571
78. M. Gross, C.L. Celum, S.R. Tabet, C.W. Kelly, A.S. Coletti, and M.A. Chesney Acceptability of a bioadhesive nonoxynol-9 gel delivered by an applicator as a rectal microbicide Sex. Transm. Dis. 26 1999 572 578
79. L. Van Damme, G. Ramjee, M. Alary, B. Vuylsteke, V. Chandeying, H. Rees, P. Sirivongrangson, L. Mukenge-Tshibaka, V. Ettiègne-Traoré, C. Uaheowitchai, S.S. Karim, B. Mâsse, J. Perriëns, and M. Laga Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial Lancet 360 2002 971 977
80. D.L. Patton, Y.T. Sweeney, J.E. Balkus, and S.L. Hillier Vaginal and rectal topical microbicide development: safety and efficacy of 1.0% Savvy (C31G) in the pigtailed macaque Sex. Transm. Dis. 33 2006 691 695
81. D.L. Patton, Y.C. Sweeney, P.K. Cummings, L. Meyn, L.K. Rabe, and S.L. Hillier Safety and efficacy evaluations for vaginal and rectal use of BufferGel in the macaque model Sex. Transm. Dis. 31 2004 290 296
82. S.R. Abner, P.C. Guenthner, J. Guarner, K.A. Hancock, J.E.J. Cummins, A. Fink, G.T. Gilmore, C. Staley, A. Ward, O. Ali, S. Binderow, S. Cohen, L.A. Grohskopf, L. Paxton, C.E. Hart, and C.S. Dezzutti A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection J. Infect. Dis. 192 2005 1545 1556
83. D.L. Patton, Y.T. Sweeney, and K.J. Paul A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model Sex. Transm. Dis. 36 2009 350 356
84. L. Peterson, K. Nanda, B.K. Opoku, W.K. Ampofo, M. Owusu-Amoako, A.Y. Boakye, W. Rountree, A. Troxler, R. Dominik, R. Roddy, and L. Dorflinger SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana PLoS One 2 2007 e1312
85. L. Van Damme, R. Govinden, F.M. Mirembe, F. Guédou, S. Solomon, M.L. Becker, B.S. Pradeep, A.K. Krishnan, M. Alary, B. Pande, G. Ramjee, J. Deese, T. Crucitti, and D. Taylor Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission N. Engl. J. Med. 359 2008 463 472
86. S. Skoler-Karpoff, G. Ramjee, K. Ahmed, L. Altini, M.G. Plagianos, B. Friedland, S. Govender, A. De Kock, N. Cassim, T. Palanee, G. Dozier, R. Maguire, and P. Lahteenmaki Efficacy of carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial Lancet 372 2008 1977 1987
87. S.S. Abdool Karim, B.A. Richardson, G. Ramjee, I.F. Hoffman, Z.M. Chirenje, T. Taha, M. Kapina, L. Maslankowski, A. Coletti, A. Profy, T.R. Moench, E. Piwowar-Manning, B. Mâsse, S.L. Hillier, and L. Soto-Torres Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women AIDS 25 2011 957 966
88. Q. Abdool Karim, S.S. Abdool Karim, J.A. Frohlich, A. Grobler, C. Baxter, L.E. Mansoor, A.B. Kharsany, S. Sibeko, K.P. Mlisana, Z. Omar, T.N. Gengiah, S. Maarschalk, N. Arulappan, M. Mlotshwa, L. Morris, and D. Taylor Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science 329 2010 1168 1174
89. S. Harman, C. Herrera, N. Armanasco, J. Nuttall, and R.J. Shattock Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide Antimicrob. Agents Chemother. 56 2012 2347 2356
90. C. Herrera, M. Cranage, I. McGowan, P. Anton, and R.J. Shattock Reverse transcriptase inhibitors as potential colorectal microbicides Antimicrob. Agents Chemother. 53 2009 1797 1807
91. C. Herrera, M. Cranage, I. McGowan, P. Anton, and R.J. Shattock Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants AIDS 25 2011 1971 1979
92. M. Stefanidou, C. Herrera, N. Armanasco, and R.J. Shattock Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention Antimicrob. Agents Chemother. 56 2012 4381 4390
93. C.S. Dezzutti, C. Shetler, A. Mahalingam, S.R. Ugaonkar, G. Gwozdz, K.W. Buckheit, and R.W. Buckheit Jr. Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention Antiviral Res. 96 2012 221 225
94. C.C. Tsai, P. Emau, Y. Jiang, B. Tian, W.R. Morton, K.R. Gustafson, and M.R. Boyd Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques AIDS Res. Hum. Retrovir. 19 2003 535 541
95. R.K. Malcolm, C.J. Forbes, L. Geer, R.S. Veazey, L. Goldman, P.J. Johan Klasse, and J.P. Moore Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques J. Antimicrob. Chemother. 68 2013 678 683
96. M. Cranage, S. Sharpe, C. Herrera, A. Cope, M. Dennis, N. Berry, C. Ham, J. Heeney, N. Rezk, A. Kashuba, P. Anton, I. McGowan, and R. Shattock Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel PLoS Med. 5 2008 e157
97. R. Singer, N. Derby, A. Rodriguez, L. Kizima, J. Kenney, M. Aravantinou, A. Chudolij, A. Gettie, J. Blanchard, J.D. Lifson, M. Piatak, J.A. Fernández-Romero, T.M. Zydowsky, and M. Robbiani The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques J. Virol. 85 2011 5504 5512
98. C.P. Neff, T. Kurisu, T. Ndolo, K. Fox, and R. Akkina A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice PLoS One 6 2011 e20209
99. M.L. Chateau, P.W. Denton, M.D. Swanson, I. McGowan, and J.V. Garcia Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice PLoS One 8 2013 e60024
100. P.A. Anton, T. Saunders, J. Elliott, E. Khanukhova, R. Dennis, A. Adler, G. Cortina, K. Tanner, J. Boscardin, W.G. Cumberland, Y. Zhou, A. Ventuneac, A. Carballo-Diéguez, L.K. Rabe, T. McCormick, H. Gabelnick, C. Mauck, and I. McGowan First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy PLoS One 6 2011 e23243
101. P.A. Anton, R.D. Cranston, A. Kashuba, C.W. Hendrix, N.N. Bumpus, N. Richardson-Harman, J. Elliott, L. Janocko, E. Khanukhova, R. Dennis, W.G. Cumberland, C. Ju, A. Carballo-Diéguez, C. Mauck, and I. McGowan RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate AIDS Res. Hum. Retrovir. 28 2012 1412 1421
102. I. McGowan, C. Hoesley, R.D. Cranston, P. Andrew, L. Janocko, J.Y. Dai, A. Carballo-Diéguez, R.K. Ayudhya, J. Piper, F. Hladik, and K. Mayer A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007) PLoS One 8 2013 e60147
103. Researchers launch first-ever phase II safety study of a rectal microbicide to prevent HIV Available from URL: http://www.mtnstopshiv.org/node/5193 (last accessed Jan 1, 2014)
104. I. McGowan Rectal microbicide development Curr. Opin. HIV AIDS 7 2012 526 533
105. A study to compare three different formulations of tenofovir 1% gel when administered rectally. NCT01575405 Available from URL: http://clinicaltrials.gov/ct2/show/NCT01575405 (last accessed Jun 1, 2014)
106. An exploratory rectal safety study of three tenofovir gel formulations. NCT01575418 Available from URL: http://clinicaltrials.gov/ct2/show/NCT01575418 (last accessed Jun 1, 2014)
107. Microbicide safety and acceptability in young men (Project Gel). NCT01283360 Available from URL: http://clinicaltrials.gov/ct2/show/NCT01283360 (last accessed Jun 15, 2014)
108. Microbicide Trials Network. MTN-014: a phase 1 crossover trial evaluating the pharmacokinetics of tenofovir reduced-glycerin 1% gel in the rectal and vaginal compartments in women Available from URL: http://www.mtnstopshiv.org/sites/default/files/attachments/MTN-014%20Version%202%200%201May2013-FINAL~CLEAN.pdf (last accessed Jun 15, 2014)
109. S. Garg, R. Kandarapu, K. Vermani, K.R. Tambwekar, A. Garg, D.P. Waller, and L.J. Zaneveld Development pharmaceutics of microbicide formulations. Part I: preformulation considerations and challenges AIDS Patient Care STDS 17 2003 17 32
110. A.B. Sassi, K.E. Bunge, B.L. Hood, T.P. Conrads, A.M. Cole, P. Gupta, and L.C. Rohan Preformulation and stability in biological fluids of the retrocyclin RC-101, a potential anti-HIV topical microbicide AIDS Res. Ther. 8 2011 27
111. S. Lard-Whiteford, D. Matecka, J. O'Rear, I. Yuen, C. Litterst, and P. Reichelderfer Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update J. Acquir. Immune Defic. Syndr. 36 2004 541 552
112. C. Lackman-Smith, C. Osterling, K. Luckenbaugh, M. Mankowski, B. Snyder, G. Lewis, J. Paull, A. Profy, R.G. Ptak, R.W. Buckheit Jr., K.M. Watson, J.E. Cummins Jr., and B.E. Sanders-Beer Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides Antimicrob. Agents Chemother. 52 2008 1768 1781
113. R.W. Buckheit Jr., and K.W. Buckheit An algorithm for the preclinical development of anti-HIV topical microbicides Curr. HIV Res. 10 2012 97 104
114. T.M. Exner, J. Correale, A. Carballo-Diéguez, L. Salomon, K.M. Morrow, C. Dolezal, and K. Mayer Women's anal sex practices: implications for formulation and promotion of a rectal microbicide AIDS Educ. Prev. 20 2008 148 159
115. M. Reece, D. Herbenick, V. Schick, S.A. Sanders, and J.D. Fortenberry Men's use and perceptions of commercial lubricants: prevalence and characteristics in a nationally representative sample of American adults J. Sex Med. 11 2014 1125 1135
116. J.L. Clark, H.J. Salvatierra, E.R. Segura, X. Salazar, K. Konda, J. Galea, J.D. Klausner, T.J. Coates, and C.F. Caceres Frequency, patterns, and preferences of lubricant use during anal intercourse within male sexual partnerships in Lima, Peru: implications for a rectal microbicide HIV prevention intervention AIDS Care 25 2012 579 585
117. S. Golombok, R. Harding, and J. Sheldon An evaluation of a thicker versus a standard condom with gay men AIDS 15 2001 245 250
118. W. Nicole A question for women's health: chemicals in feminine hygiene products and personal lubricants Environ. Health Perspect. 122 2014 A70 A75
119. M.J. Fevola, L. Gentner, N. Ahmad, and J.J. Librizzi Getting intimate with polymers: personal lubricants Cosmet. Toilet. 123 2008 59 68
120. S. Geibel Condoms and condiments: compatibility and safety of personal lubricants and their use in Africa J. Int. AIDS Soc. 16 2013 18531
121. K. Rebe, G. De Swardt, P. Berman, H. Struthers, and J. McIntyre Sexual lubricants in South Africa may potentially disrupt mucosal surfaces and increase HIV transmission risk among men who have sex with men S. Afr. Med. J. 104 2014 49 51
122. M. Gross, S. Buchbinder, C. Celum, P. Heagerty, and G.R.R. Seage Rectal microbicides for U.S. gay men. Are clinical trials needed? Are they feasible? HIVNET Vaccine Preparedness Study Protocol Team Sex. Transm. Dis. 25 1998 296 302
123. D.M. Phillips, K.M. Sudol, C.L. Taylor, L. Guichard, R. Elsen, and R.A. Maguire Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs Contraception 70 2004 107 110
124. R.N. Fichorova, L.D. Tucker, and D.J. Anderson The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission J. Infect. Dis. 184 2001 418 428
125. O. Begay, N. Jean-Pierre, C.J. Abraham, A. Chudolij, S. Seidor, A. Rodriguez, B.E. Ford, M. Henderson, D. Katz, T. Zydowsky, M. Robbiani, and J.A. Fernandez-Romero Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro AIDS Res. Hum. Retrovir. 27 2011 1019 1024
126. C.S. Dezzutti, E.R. Brown, B. Moncla, J. Russo, M. Cost, L. Wang, K. Uranker, R. Kunjara Na Ayudhya, K. Pryke, J. Pickett, M.A. LeBlanc, and L.C. Rohan Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity PLoS One 7 2012 e48328
127. J. Jagur-Grodzinski Polymeric gels and hydrogels for biomedical and pharmaceutical applications Polym. Adv. Technol. 21 2010 27 47
128. A. Carballo-Diéguez, J. Bauermeister, A. Ventuneac, C. Dolezal, and K. Mayer Why rectal douches may be acceptable rectal-microbicide delivery vehicles for men who have sex with men Sex. Transm. Dis. 37 2010 228 233
129. M. Javanbakht, S. Stahlman, J. Pickett, M.A. LeBlanc, and P.M. Gorbach Prevalence and types of rectal douches used for anal intercourse: results from an international survey BMC Infect. Dis. 14 2014 95
130. L.R. Harris, and L. Roberts Treatments for irritable bowel syndrome: patients' attitudes and acceptability BMC Complement. Altern. Med. 8 2008 65
131. I. McGowan Rectal microbicides: can we make them and will people use them? AIDS Behav. 15 Suppl. 1 2011 S66 S71
132. A. Carballo-Diéguez, C. Dolezal, J.A. Bauermeister, W. O'Brien, A. Ventuneac, and K. Mayer Preference for gel over suppository as delivery vehicle for a rectal microbicide: results of a randomised, crossover acceptability trial among men who have sex with men Sex. Transm. Infect. 84 2008 483 487
133. H.A. Pines, P.M. Gorbach, R.E. Weiss, K. Hess, R. Murphy, T. Saunders, J. Brown, P.A. Anton, and R.D. Cranston Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial AIDS Behav. 17 2013 1002 1015
134. EMEA Guideline on Non-clinical Local Tolerance Testing of Medicinal Products. London, UK 2014
135. FDA Guidance for Industry Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients. Rockville, MD, USA 2005
136. L.L. Wang, W.S. Zheng, S.H. Chen, and X.Q. Fang Development of in situ gelling and bio adhesive 5-fluorouracil enema PLoS One 8 2013 e71037
137. Annual review of cosmetic ingredient safety assessments - 2001/2002 Int. J. Toxicol. 22 Suppl. 1 2003 1 35
138. T.R. Moench, R.J. Mumper, T.E. Hoen, M. Sun, and R.A. Cone Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse BMC Infect. Dis. 10 2010 331
139. K. Nakanishi, M. Masada, and T. Nadai Effect of pharmaceutical adjuvants on the rectal permeability to drugs. IV. Effect of pharmaceutical adjuvants on the rectal permeability to macromolecular compounds in the rat Chem. Pharm. Bull. 32 1984 1628 1632
140. Q. Yu, Z. Wang, P. Li, and Q. Yang The effect of various absorption enhancers on tight junction in the human intestinal Caco-2 cell line Drug Dev. Ind. Pharm. 39 2013 587 592
141. T. Mukherjee, E. Squillantea, M. Gillespieb, and J. Shao Transepithelial electrical resistance is not a reliable measurement of the Caco-2 monolayer integrity in Transwell Drug Deliv. 11 2004 11 18
142. V. Jannin, G. Lemagnen, P. Gueroult, D. Larrouture, and C. Tuleu Rectal route in the 21st century to treat children Adv. Drug Deliv. Rev. 73 2014 39 49
143. A. Reid, N. Thomas, K. Palin, and P. Gould Formulation of fenbufen suppositories. I. Quantitative histological assessment of the rectal mucosa of rats following treatment with suppository bases Int. J. Pharm. 40 1987 181 185
144. E.J. van Hoogdalem, C. Vermeij-Kerrs, A.G. de Boer, and D.D. Breimer Topical effects of absorption enhancing agents on the rectal mucosa of rats in vivo J. Pharm. Sci. 79 1990 866 870
145. C. De Muynck, C. Cuvelier, D. Van Steenkiste, L. Bonnarens, and J.P. Remon Rectal mucosa damage in rabbits after subchronical application of suppository bases Pharm. Res. 8 1991 945 950
146. I. Sechter, E. Touitou, and M. Donbrow The influence of a non-ionic surfactant on rectal absorption of virus particles Arch. Virol. 106 1989 141 143
147. N.A. Louissaint, S. Nimmagadda, E.J. Fuchs, R.P. Bakshi, Y.J. Cao, L.A. Lee, J. Goldsmith, B.S. Caffo, Y. Du, K.E. King, F.A. Menendez, M.S. Torbenson, and C.W. Hendrix Distribution of cell-free and cell-associated HIV surrogates in the colon after simulated receptive anal intercourse in men who have sex with men J. Acquir. Immune Defic. Syndr. 59 2012 10 17
148. M.H. Henderson, G.M. Couchman, D.K. Walmer, J.J. Peters, D.H. Owen, M.A. Brown, M.L. Lavine, and D.F. Katz Optical imaging and analysis of human vaginal coating by drug delivery gels Contraception 75 2007 142 151
149. F.J. Leyva, R.P. Bakshi, E.J. Fuchs, L. Li, B.S. Caffo, A.J. Goldsmith, A. Ventuneac, A. Carballo-Diéguez, Y. Du, J.P. Leal, L.A. Lee, M.S. Torbenson, and C.W. Hendrix Isoosmolar enemas demonstrate preferential gastrointestinal distribution, safety, and acceptability compared with hyperosmolar and hypoosmolar enemas as a potential delivery vehicle for rectal microbicides AIDS Res. Hum. Retrovir. 29 2013 1487 1495
150. A. Carballo-Diéguez, T. Exner, C. Dolezal, R. Pickard, P. Lin, and K.H. Mayer Rectal microbicide acceptability: results of a volume escalation trial Sex. Transm. Dis. 34 2007 224 229
151. Y. Kinouchi, Y. Takeichi, and N. Yata A novel method for the preclinical assessment of rectal irritation J. Pharm. Pharmacol. 48 1996 310 315
152. L. Wang, R.L. Schnaare, C. Dezzutti, P.A. Anton, and L.C. Rohan Rectal microbicides: clinically relevant approach to the design of rectal specific placebo formulations AIDS Res. Ther. 8 2011 1 10
153. H. Agashe, M. Hu, and L. Rohan Formulation and delivery of microbicides Curr. HIV Res. 10 2012 88 96
154. WHO Use and Procurement of Additional Lubricants for Male and Female Condoms: WHO/UNFPA/FHI. Advisory Note. Geneva, Switzerland 2012
155. E.J. Fuchs, L.A. Lee, M.S. Torbenson, T.L. Parsons, R.P. Bakshi, A.M. Guidos, R.L. Wahl, and C.W. Hendrix Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission J. Infect. Dis. 195 2007 703 710
156. K.M. Sudol, and D.M. Phillips Relative safety of sexual lubricants for rectal intercourse Sex. Transm. Dis. 31 2004 346 349
157. P.M. Gorbach, R.E. Weiss, E. Fuchs, R.A. Jeffries, M. Hezerah, S. Brown, A. Voskanian, E. Robbie, P. Anton, and R.D. Cranston The slippery slope: lubricant use and rectal sexually transmitted infections: a newly identified risk Sex. Transm. Dis. 39 2012 59 64
158. L.C. Rohan, H. Yang, and L. Wang Rectal pre-exposure prophylaxis (PrEP) Antiviral Res. 100 Suppl. 2013 S17 S24
159. S. Garg, K. Tambwekar, K. Vermani, R. Kandarapu, A. Garg, D. Waller, and L. Zaneveld Development pharmaceutics of microbicide formulations. Part II: formulation, evaluation, and challenges AIDS Patient Care STDS 17 2003 377 399
160. FDA Guidance for industry vaginal microbicides: development for the prevention of HIV infection, Silver Spring, MD, USA Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM328842.pdf 2012 (last accessed Jul 1, 2014)
161. FDA Guidance for industry Q1A(R2) stability testing of new drug substances and products. Rockville, MD, USA Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073369.pdf 2003 (last accessed Jul 1, 2014)
162. A. Mahalingam, A.P. Simmons, S.R. Ugaonkar, K.M. Watson, C.S. Dezzutti, L.C. Rohan, R.W.J. Buckheit, and P.F. Kiser Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1 Antimicrob. Agents Chemother. 55 2011 1650 1660
163. L. Li, Y. Ben, S. Yuan, S. Jiang, J. Xu, and X. Zhang Efficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1 PLoS One 7 2012 e37381
164. A. Ventuneac, A. Carballo-Diéguez, I. McGowan, R. Dennis, A. Adler, E. Khanukhova, C. Price, T. Saunders, C. Siboliban, and P. Anton Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men AIDS Behav. 14 2010 618 628
165. A. Carballo-Diéguez, R. Giguere, C. Dolezal, J. Bauermeister, C.S. Leu, J. Valladares, L.C. Rohan, P.A. Anton, R.D. Cranston, I. Febo, K. Mayer, and I. McGowan Rectal-specific microbicide applicator: evaluation and comparison with a vaginal applicator used rectally AIDS Behav. 18 2014 1734 1745
166. J.G. Vail, J.A. Cohen, and K.L. Kelly Improving topical microbicide applicators for use in resource-poor settings Am. J. Public Health 94 2004 1089 1092
167. J.A. Cohen, V. Brache, J. Foster, L. Cochon, M. Callahan, and J. Schwartz A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel Sex. Transm. Dis. 40 2013 476 481
168. G.F. Doncel, and M.R. Clark Preclinical evaluation of anti-HIV microbicide products: new models and biomarkers Antiviral Res. 88 Suppl. 1 2010 S10 S18
169. L.C. Rohan, B.J. Moncla, R.P. Kunjara Na Ayudhya, M. Cost, Y. Huang, F. Gai, N. Billitto, J.D. Lynam, K. Pryke, P. Graebing, N. Hopkins, J.F. Rooney, D. Friend, and C.S. Dezzutti In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide PLoS One 5 2010 e9310
170. A.S. Ham, S.R. Ugaonkar, L. Shi, K.W. Buckheit, H. Lakougna, U. Nagaraja, G. Gwozdz, L. Goldman, P.F. Kiser, and R.W. Buckheit Jr. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection J. Pharm. Sci. 101 2012 1423 1435
171. D.H. Owen, J.J. Peters, S.L. Kieweg, A.R. Geonnotti, R.L. Schnaare, and D.F. Katz Biophysical analysis of prototype microbicidal gels J. Pharm. Sci. 96 2007 661 669
172. WHO Male latex condom: specification, prequalification and guidelines for procurement, 2010 (revised April 2013). Geneva, Switzerland Available from URL: http://whqlibdoc.who.int/publications/2010/9789241599900-eng.pdf?ua=1 (last accessed Jul 1, 2014)
173. N. Gagné, H. Cormier, R.F. Omar, A. Desormeaux, P. Gourde, M.J. Tremblay, J. Juhasz, D. Beauchamp, J.E. Rioux, and M.G. Bergeron Protective effect of a thermoreversible gel against the toxicity of nonoxynol-9 Sex. Transm. Dis. 26 1999 177 183
174. H. Yang, M.A. Parniak, C.E. Isaacs, S.L. Hillier, and L.C. Rohan Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781 AAPS J. 10 2008 606 613
175. R.S. Veazey, R.J. Shattock, P.J. Klasse, and J.P. Moore Animal models for microbicide studies Curr. HIV Res. 10 2012 79 87
176. J.G. Garcia-Lerma, and W. Heneine Animal models of antiretroviral prophylaxis for HIV prevention Curr. Opin. HIV AIDS 7 2012 505 513
177. J.L. Adams, and A.D. Kashuba Formulation, pharmacokinetics and pharmacodynamics of topical microbicides Best Pract. Res. Clin. Obstet. Gynaecol. 26 2012 451 462
178. B. Sarmento, F. Andrade, S.B. da Silva, F. Rodrigues, J. das Neves, and D. Ferreira Cell-based in vitro models for predicting drug permeability Expert Opin. Drug Metab. Toxicol. 8 2012 607 621
179. J. Nuttall, A. Kashuba, R. Wang, N. White, P. Allen, J. Roberts, and J. Romano Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques Antimicrob. Agents Chemother. 56 2012 103 109
180. N. Richardson-Harman, C. Mauck, I. McGowan, and P. Anton Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study AIDS Res. Hum. Retrovir. 28 2012 1422 1433
181. R.K. Malcolm, D. Lowry, P. Boyd, L. Geer, R.S. Veazey, L. Goldman, P.J. Klasse, R.J. Shattock, and J.P. Moore Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application J. Antimicrob. Chemother. 69 2014 1325 1329
182. E.E. To, C.W. Hendrix, and N.N. Bumpus Dissimilarities in the metabolism of antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues Biochem. Pharmacol. 86 2013 979 990
183. R.D. Cranston, C. Hoesley, A. Carballo-Diéguez, C.W. Hendrix, M. Husnik, L. Levy, W. Hall, L. Soto-Torres, and A.M. Nel A randomized male tolerance study of dapivirine gel following multiple topical penile exposures (MTN 012/IPM 010) AIDS Res. Hum. Retrovir. 30 2014 184 189
184. K.M. Morrow, and C. Hendrix Clinical evaluation of microbicide formulations Antiviral Res. 88 2010 S40 S46
185. K.M. Morrow, and M.S. Ruiz Assessing microbicide acceptability: a comprehensive and integrated approach AIDS Behav. 12 2008 272 283
186. D.R. Friend, B. Devlin, and C. Gilmour Microbicide formulation development: scale-up, affordability, and intellectual property issues J. das Neves, B. Sarmento, Drug Delivery and Development of Anti-HIV Microbicides 2014 535 547 (Pan Stanford, Singapore)
187. F. Terris-Prestholt, A.M. Foss, A.P. Cox, L. Heise, G. Meyer-Rath, S. Delany-Moretlwe, T. Mertenskoetter, H. Rees, P. Vickerman, and C.H. Watts Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices BMC Infect. Dis. 14 2014 14
188. J.J. Kinsler, W.E. Cunningham, C.R. Nurena, C. Nadjat-Haiem, B. Grinsztejn, M. Casapia, O. Montoya-Herrera, J. Sanchez, and J.T. Galea Using conjoint analysis to measure the acceptability of rectal microbicides among men who have sex with men in four South American cities AIDS Behav. 16 2012 1436 1447
189. MDS Working Groups The microbicide development strategy 2006 Alliance for Microbicide Development Silver Spring, MD, USA Available from URL: http://www.microbicide.org/uploads/3/1/2/1/3121935/microbicide-development
190. J. das Neves, M.M. Amiji, M.F. Bahia, and B. Sarmento Nanotechnology-based systems for the treatment and prevention of HIV/AIDS Adv. Drug Deliv. Rev. 62 2010 458 477
191. B. Sarmento, and J. das Neves Nanosystem formulations for rectal microbicides: a call for more research Ther. Deliv. 3 2012 1 4
192. S. Telwatte, K. Moore, A. Johnson, D. Tyssen, J. Sterjovski, M. Aldunate, P.R. Gorry, P.A. Ramsland, G.R. Lewis, J.R. Paull, S. Sonza, and G. Tachedjian Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1 Antiviral Res. 90 2011 195 199
193. C.S. Dezzutti, V.N. James, A. Ramos, S.T. Sullivan, A. Siddig, T.J. Bush, L.A. Grohskopf, L. Paxton, S. Subbarao, and C.E. Hart In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission Antimicrob. Agents Chemother. 48 2004 3834 3844
194. D.L. Patton, Y.T. Cosgrove Sweeney, T.D. McCarthy, and S.L. Hillier Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model Antimicrob. Agents Chemother. 50 2006 1696 1700
195. J. das Neves, J. Michiels, K.K. Ariën, G. Vanham, M. Amiji, M.F. Bahia, and B. Sarmento Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine Pharm. Res. 29 2012 1468 1484
196. J. das Neves, F. Araújo, F. Andrade, J. Michiels, K.K. Ariën, G. Vanham, M. Amiji, M.F. Bahia, and B. Sarmento In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine Mol. Pharm. 10 2013 2793 2807
197. M.M. Patel Getting into the colon: approaches to target colorectal cancer Expert Opin. Drug Deliv. 2014 1 8
198. M. Li, D.L. Patton, Y. Cosgrove-Sweeney, D. Ratner, L.C. Rohan, A.M. Cole, P.M. Tarwater, P. Gupta, and B. Ramratnam Incorporation of the HIV-1 microbicide cyanovirin-N in a food product J. Acquir. Immune Defic. Syndr. 58 2011 379 384
199. Q. Zhu, J. Talton, G. Zhang, T. Cunningham, Z. Wang, R.C. Waters, J. Kirk, B. Eppler, D.M. Klinman, Y. Sui, S. Gagnon, I.M. Belyakov, R.J. Mumper, and J.A. Berzofsky Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection Nat. Med. 18 2012 1291 1296